Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 181

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 181
---
 |   |
| Exercise of stock warrants                      |     |             | — |     |        | — |     |        |  1,066,767 |     |        |   7,467 |     |            |  1,363,680 |   |     |             | —           |   |     |               |  1,371,147 |   |
| Sale of common stock                            |     |             | — |     |        | — |     |        |  4,008,294 |     |        |  28,059 |     |            |  5,584,724 |   |     |             | —           |   |     |               |  5,612,782 |   |
| Offering costs                                  |     |             | — |     |        | — |     |        |            |     |        |         |     |            | (1,261,898 | ) |     |             | —           |   |     |               | (1,261,898 | ) |
| Net loss                                        |     |             | — |     |        | — |     |        |          — |     |        |       — |     |            |          — |   |     |             | (9,039,831  | ) |     |               | (9,039,831 | ) |
| Balance at December 31, 2024                    |     |             | — |     |        | — |     |        | 15,227,619 |     | $      | 106,593 |     | $          | 56,139,753 |   |     | $           | (53,644,310 | ) |     | $             |  2,602,036 |   |
| Balance                                         |     |             | — |     |        | — |     |        | 15,227,619 |     | $      | 106,593 |     | $          | 56,139,753 |   |     | $           | (53,644,310 | ) |     | $             |  2,602,036 |   |

<div align='center'>The accompanying notes are an integral part of these consolidated financial statements.</div>

| F-5 |

<div align='center'>bioAffinity Technologies, Inc.

Consolidated Statements of Cash Flows

For the Years Ended December 31,